AGC Biologics has announced a change in executive leadership, appointed by their board of directors. Robert (Bob) Broeze will retire on March 5th, 2019 after a 35-year career in the biopharmaceutical industry. Mark Womack, previously the Senior Vice President of Integration Management and Business Excellence for AGC Biologics, will succeed Broeze as the Chief Business Officer, effective immediately.
Broeze joined CMC Biologics (now AGC Biologics) in 2015 as Senior Vice President of Global Business Development, bringing more than 30 years of industry experience to the role.
"Bob played a key role in shaping and directing our successful business development program and has been an exceptional leader, passionate about our mission and committed to our principles and values," said Gustavo Mahler, PhD, Chief Executive Officer. "Bob's leadership has been instrumental in realizing our vision and achieving significant growth of our business. We wish him well in his retirement and appreciate his support as we transition leadership."
Womack has served on AGC Biologics' Executive Team in the role of Senior Vice President of Integration Management and Business Excellence since beginning of 2018. Womack has over 25 years of experience leading large-scale business integrations and transformations of Fortune 200 client companies both as the COO of several international management consultancies, as well as with his own management and leadership consultancy corporation.
"I am honored and excited to succeed Bob as Chief Business Officer and provide differentiated value to the world's pharmaceutical companies as a leading global Contract Development and Manufacturing Organization. AGC Biologics is being embraced by customers and partners and is emerging as the leading CDMO in the industry," Womack said.
"Mark's knowledge and leadership abilities will enable AGC Biologics to further grow its business development capabilities and infrastructure. I look forward to continuing to work with Mark in his new role," Mahler said.